Edwards Lifesciences Is Skyrocketing

Shares of Edwards Lifesciences Corp. EW are skyrocketing today on news that the company had favorable data for its "Sapiens" heart valve. The FDA subsequently approved a follow on trial, which is being seen as a positive for the products approval. The company also received a favorable write up in the New England Journal of Medicine. Edwards also received two upgrades in price targets this morning, from Deutsche Bank and Piper Jaffray. Shares are currently up $7.47 or 12.51% to trade at $67.17. A business summary for Edwards reads: "Edwards Lifesciences Corporation provides products and technologies designed to treat advanced cardiovascular diseases. It offers products and technologies for heart valve therapy, critical care, cardiac surgery systems, and vascular diseases."